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Main article [word count: 3519] Introduction
The increased prevalence of cardiovascular disease (CVD) in developing countries is placing a huge burden on health care services (1) (2) (3) . India, in particular, with a large number of individuals with hypertension, dyslipidemia, diabetes and CVD, is facing a significant healthcare delivery challenge (4) . Patients with CVD should receive antiplatelet therapy and drugs to lower blood pressure (BP) and low-density lipoprotein cholesterol (LDLc) (5) (6) (7) (8) (9) . However, the use of preventive cardiovascular medications is disappointingly low (10) (11) (12) . The cost and complexity of multi-drug regimens impacts adversely on adherence to such treatment and therefore, on its effectiveness (5, (13) (14) (15) (16) (17) . The use of a cardiovascular polypill has shown to improve adherence to essential cardiovascular drugs and risk factor control (18) (19) (20) .
The Use of Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial (21) demonstrated that a polypill based strategy improved adherence to prescribed therapy, and reduced BP and LDLc, compared to usual care in patients with or at high risk of CVD. Since the constituent drugs of the polypill used in UMPIRE are off-patent generics, this polypill can be manufactured at low cost. However, pharmaceutical companies are only likely to manufacture the polypill if the scale of prescribing compensates for small profit margins. Robust evidence on the cost-effectiveness of the polypill is therefore required to establish the polypill as part of an Indian CVD preventive strategy and to support the investment case for healthcare funders. India is estimated to have the largest number of prevalent cases of CVD in the world due to a high incidence rate and large population (more than 50% below the age of 25)(4).
Further, wide variation in socio-economic status with a substantial proportion of the
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6 population living below the poverty line with a predilection to have CVD at a young-age necessitates affordable and accessible secondary prevention treatment for CVD (22) .
Although the cost-effectiveness of pharmacological and lifestyle modification interventions to prevent CVD have been evaluated in decision modeling studies [few examples: (23) (24) (25) (26) ], the cost-effectiveness of a polypill strategy using patient outcomes derived from a randomized controlled trial (RCT) in an Indian context is unknown. The RUPEE-IND (Researching UMPIRE Processes, an Economic Evaluation in India) study was designed to investigate the impact of switching high risk CVD patients from usual care to a polypill strategy. This paper reports the "within-trial" cost-effectiveness of the polypill strategy relative to usual care in India.
Methods

UMPIRE trial
The UMPIRE trial was an open label, RCT of a polypill-based strategy, compared to usual care, in 2004 patients with or at high risk of CVD in India, United Kingdom (UK), Ireland, and Netherlands. The trial was conducted between Feb 2010
and Jan 2013 and ethics approval was obtained at each of the participating trial sites.
Full details of the trial protocol and primary outcome results were published previously (21) . In India, 1000 individuals aged ≥18 years and of both sexes with or at high risk of CVD (≥15% CVD risk over 10 years), were randomized to receive the polypill or usual care. Two versions of the polypill were used: Red Heart Pill (RHP) version 1: aspirin 75mg, lisinopril 10mg, simvastatin 40mg, atenolol 50mg or RHP version 2: aspirin 75mg, lisinopril 10mg, simvastatin 40mg, hydrochlorothiazide 12.5 mg. The polypill was prescribed to be taken orally, once daily and regarded as 'background treatment' to which other medications could be added to achieve physician recommended BP or
cholesterol targets, and/or to treat comorbidities. The RHPs were manufactured by Dr.
Reddy's Laboratories (Hyderabad, India) and were provided without cost to trial participants.
Patient characteristics
The trial population consisted of 501 individuals in the polypill arm and 499
in the usual care arm in India. The baseline characteristics of the two groups were similar [ Table 1 ] and were typical of CVD presentation in India, i.e. occurrence of CVD at a relatively young age, high prevalence of co-morbid conditions (diabetes), and the presence of higher CVD burden in low socio-economic strata.
Resource utilization and costs within trial
Costs per participant were determined from health care utilization and unit costs for these services. Data on treatment or cardiovascular-related use of health services over the study period were extracted from UMPIRE case report forms at 1 month, 6 months, 12 months, 18 months and at the trial end. These data included: medication use, consultations with healthcare professionals, emergency department attendances, and hospitalizations related to prescribed medications. Price estimates of the polypill were derived from five scenarios (Box 1). The cost of most events/hospitalizations was limited to a defined acute period, but stroke and renal failure events often require care for months or years after the initial hospitalization. Hence, for strokes we applied a cost that reflects a one-year period and for renal failure we applied a 6-month recurring dialysis cost that continued to the end of the study. A mean cost per unit was applied to resource use by each participant and to the clinical events reported by all study participants. Unit costs for healthcare services was collected from the participating trial sites using a standardized cost survey form (#Appendix 2).
Within trial Cost-Effectiveness Analysis
The analysis was carried out from a health sector perspective. Consistent with this perspective, we only considered direct medical costs incurred by patients and care providers. Indirect costs (productivity lost) and travel costs incurred by patients and their families/caregivers were not considered. All analyses used the 15-month trial duration and no discount rate was applied. Categorical data were reported as frequencies (percentages) and continuous data as means with standard errors. We performed an intention to treat (ITT) analysis to assess both effects and costs over the trial duration. At the trial end, complete data on effectiveness outcomes (adherence to
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A C C E P T E D M A N U S C R I P T 9 therapy, BP and LDLc) were available for 91.1% participants. Adherence to therapy was defined as self-reported use of antiplatelet, statin, and ≥2BP-lowering drugs, for at least 4 days during the week preceding the visit at baseline and at the trial end (21) . The EQ5D questionnaire was applied to assess quality of life and we report the Visual Analogue Scale (VAS) results between the two groups because currently there is no value set available to calculate EQ5D utility scores in India. For the base-case ITT analysis, we imputed missing data using the last observation carried forward method.
Incremental cost-effectiveness ratios (ICERs) were calculated as the difference in costs divided by the difference in effects between the polypill and usual care group. The ICER is a summary measure indicating the cost-effectiveness of an intervention compared to an alternative. In situations where the intervention costs are higher than usual care, the ICER represents the additional costs per additional unit of benefit. Where an intervention or usual care is dominant (more effective and less expensive than the comparator), the ICER is negative and is not meaningful (27) . The cost-effectiveness analysis (CEA) results are reported as incremental cost per 10% increase in adherence and per unit reduction in SBP (mmHg) and LDLc (mg/dl). We report ICERs for the different polypill price scenarios, where appropriate, and do not report negative ICERs.
Bootstrap sampling was used to estimate uncertainty around the cost and effectiveness estimates (28, 29) . CEA results from bootstrap replications were plotted on a costeffectiveness plane and using a cost-effectiveness acceptability curve (CEAC) against a range of willingness to pay (WTP) values (30) . All statistical analyses were completed using Microsoft Office Excel 2007, and STATA (version 12.0 SE; StataCorp, TX, USA).
Sensitivity analyses
We conducted several deterministic sensitivity analyses to examine uncertainty in the key input variables (e.g. effectiveness, cost of drug), which could
potentially influence the ICER. Further, in a multivariable sensitivity analysis, we simulated the best (and worst) case scenarios using the maximum effectiveness of the polypill, minimum cost of the polypill, minimum cost of healthcare visits and minimum cost of hospitalizations/events. Minimum/maximum cost was defined by lower/upper bound of 95% confidence interval (CI).
Sub-group analyses
Several subgroups were analyzed to explore potential cost differences:
established CVD versus high CVD risk patients, age, gender, education strata, income class, employment status, public vs. private health setting, and adherence to prescribed therapy, as defined in the UMPIRE trial (31) . Table 2 ].
Results
Effectiveness of polypill
Medication, healthcare visits and hospitalization costs
Compared to the usual care, the cost of medications per person was significantly lower with the polypill strategy at 15 months (cost difference of $242.8 per person, 95% CI: $-318.7, $-166.7, p<0.01). There was no significant difference in costs associated with out-patient healthcare visits between the two treatment strategies.
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However, the costs of hospitalizations were significantly higher with the polypill strategy compared to usual care (cost difference of $39.8 per person, 95% CI: $4.7, $74.7, p=0.03). Overall, the average cost, summing the cost of medications, out-patient healthcare visits and hospitalizations per patient, was significantly lower with the polypill strategy compared to usual care (cost difference of $202.9 per person, 95% CI:
$-286.4, $-119.4, p < 0.01) [ Table 3 ].
Cost effectiveness
In scenarios A-D, we found that the polypill strategy dominated usual care is an 80% probability that the polypill would be cost-effective. The probability rises to about 100% for WTP above $800 per 10% increase in adherence. Similarly, for scenario E: at $800 WTP for a 10% increase in adherence, there is an 80% probability that the polypill would be cost-effective. However, the probability rises to 100% at the WTP above $1200 per 10% increase in adherence.
Sensitivity analysis results
Our cost-effectiveness results were robust to several sensitivity analyses.
The unit cost of healthcare visits had minimal impact on cost-effectiveness estimates, whereas the ICER was most sensitive to the effectiveness and cost of polypill. In all oneway sensitivity analyses and best-case scenarios usual care therapy was dominated by the polypill strategy, confirming that the polypill is a cost-effective option in the Indian context (Online Table 1 ). In the worst case-scenario, the ICERs for the 10% increase in adherence, per unit reduction in LDLc and SBP was $373, $504, and $202, respectively.
Subgroup analyses results
Across all major sub-groups, the participants in the polypill group incurred significantly less cost, compared to the usual care group (p<0.01). Increased cost
savings were particularly noted in people aged ≥ 55 years, males, and patients at high risk of cardiovascular disease. Individuals with co-morbid conditions such as diabetes and those with high adherence rates had two times greater cost savings with the polypill strategy vs. usual care. [Online Table 2 ].
Discussion
This trial-based cost effectiveness analysis found the polypill strategy to be cost-effective with greater clinical benefits (improved adherence, lower SBP and LDLc)
at lower healthcare cost, compared to usual care in patients with or at high risk of CVD in India. The results were largely driven by the overall net savings in the medication cost with the polypill strategy. The polypill strategy had a very high probability of being cost-saving up to a maximum price of $0.54 per day. At a higher price (>$0.54/pill) the polypill may still be cost-effective depending on decision makers' maximum willingness to pay for a unit of health benefit.
RUPEE is the first study to report the cost-effectiveness of a cardiovascular polypill strategy for secondary prevention of CVD in India. The main strength of this analysis is that it uses patient level data from a well-designed RCT. The trial followed a standardized protocol and measurement tools across 28 participating sites in India to produce strong evidence on the effectiveness of a polypill compared to usual care. Our CEA results are robust to a number of scenario, subgroup and sensitivity analyses.
The CEA has limitations. The analysis is based on the prices of drugs as they stood at the end of the trial in 2012. The results may not hold if there are future price changes in the cost of preventive CVD medicines. However, we have conducted a range of sensitivity analysis around the price of the medication, so this should capture any future changes in the price. The study assumed the market price of a polypill based on
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14 different pricing strategies, which is helpful to understand the threshold at which the polypill is or is not considered cost-effective. The current study could not estimate the likely effect of long-term polypill-based care on cardiovascular events for several reasons -there were relatively few events, follow-up was short considering there is a lag-time of a year or so for the full extent of cardiovascular benefits to appear (e.g., for cholesterol lowering effect (34-36)), and also patients in both groups are generally treated more intensively than average in a clinical trial setting. Furthermore, in an unblinded trial such as this one, it remains possible that differential treatment and/or reporting was provided to the participants in the polypill group.
Multidrug regimens (aspirin, beta-blockers, ACEI, or lipid-lowering drugs) for secondary prevention of CVD have been shown to be cost-effective according to World
Health Organization (WHO) standards (37) . But, a polypill strategy would be more costeffective than usual care. Previous studies have modelled CVD reduction on the assumption of aspirin adherence and sustained BP and LDL-c reductions and the established relationships between these risk factor changes and CVD events in past trials (23, 24, 37, 38) . A decision modelling study conducted within the Dutch health system found that the polypill would be a cost-effective strategy in individuals with a 10 year cardiovascular (CV) risk of 7.5% (26) . Another CEA of the polypill in a high CV risk population (≥15% CV risk over 10 years) in Latin America performed using a Markov model, reported that the provision of a polypill to those with or at high risk of CVD would yield an acceptable ICER: $34-$36 per QALY (38) .
A recent study in India evaluated the cost-effectiveness of policies to expand coverage, access and use of CVD prevention drugs including a polypill strategy in patients with acute myocardial infarction for secondary prevention of CVD (39) . This study found that a policy to expand access to the polypill is the most cost-effective where we found the polypill strategy to be dominant, is unlikely to alter the existing conclusions that there is a strong investment case for such a strategy.
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The disparity in the use of cardio-protective drugs between countries is extremely high (10, 11, 41) . Much of the difference in the use of CVD medications is explained by a strong positive correlation with a countries' GDP and health expenditures per capita (42) . This is particularly seen in the use of statins, which are more expensive and are used relatively infrequently in South Asia but are the most used drug in high-income countries (10, 42) . Apparently, the main barrier to the use of preventive cardiovascular drug is high out-of-pocket health expenditures. However, the
16 use of aspirin, an inexpensive drug, is also low. Thus, a possible barrier to secondary prevention could be related to adherence to multi-medication therapy. In addition, a sizeable proportion of the Indian population live below the poverty line and treatment for CVD can incur catastrophic health expenditures (43, 44) . It is thus, important to advocate for low-cost affordable treatment options for chronic care of CVD. The polypill has the advantage of being one pill instead of four, making it a less complex regimen which could promote more widespread use and greater adherence (45) (46) (47) . The simplified treatment regimen and lower cost of the polypill relative to usual care further drives the polypill's dominance in our CEA. It is important to note that the polypill was found to be effective and cost-effective, in improving adherence and lowering SBP and LDLc, despite using simvastatin, whereas the usual care strategy used recent and more potent statins [in the Indian pharmaceutical market, simvastatin appears to be more expensive than atorvastatin]. Therefore, the impact of a polypill could be greater with the use of more potent and less expensive statins.
Conclusion
In line with the WHO "25x25" goal and recognizing the urgent need to identify and promote the most cost-effective interventions for CVD prevention, our findings offer a cost-effective option of delivering and improving care for CVD patients in low-resource settings with a polypill strategy. A low-cost polypill would improve the access, availability and affordability of CVD prevention treatment for millions of people living with cardiovascular disease globally. 
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